Risperidone (and 9-hydroxyrisperidone)

Description
Risperidone and 9-hydroxyrisperidone by LC-MS/MS.
Clinical details
Risperidone (Risperidal®) is an atypical or ‘second generation' antipsychotic. Side-effects of risperidone may include somnolence, nausea, dizziness, and anxiety. There is a risk of hypotension at higher doses. Risperidone can be administered either orally, or by intra-muscular injection. Oral dosage is normally 2-6 mg/d (BNF recommended limit). Patients receiving intra-muscular injection are normally given up to 50 mg every two weeks. Risperidone is metabolised by hydroxylation and N-demethylation. The 9-hydroxylated metabolite, 9-hydroxyrisperidone, is an active metabolite that also accumulates in plasma. Racemic 9-hydroxyrisperidone is itself licensed for the management of schizophrenia (Paliperidone®). Although a target range in therapy has not been established, a steady state reference range of 20-60 µg/L (risperidone + total 9-hydroxyrisperidone) has been suggested.
Units
µg/L
Testing site
Synnovis : Reference Services : King's College Hospital
Laboratory
Therapeutic Drug Monitoring
Sample type and volume required
2mL of EDTA whole blood preferred. Serum or plasma can be used if required.
Storage and transport
Please refrigerate (if possible) if not sending immediately. Send by first class post.
Turnaround time
5 working days.

Last updated:

Back to search